naltrexone has been researched along with Liver Diseases in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Askgaard, G; Nielsen, AS; Thiele, M | 1 |
| Ayyala, D; Bottyan, T; Dodge, JL; Gonzalez, JL; Han, H; Pimienta, M; Stager, K; Stolz, A; Terrault, NA; Tien, C; Yoo, J | 1 |
| Du, Y; Sun, L; von Moltke, L; Yagoda, S | 1 |
| Barter, Z; Rowland Yeo, K; Sun, L; von Moltke, L | 1 |
| Du, J; Liang, R; Tang, B; Wang, H; Wang, L; Yuan, P; Zhang, Y | 1 |
| Dilzer, SC; Dong, Q; Dunbar, JL; Ehrich, EW; Lasseter, KC; Silverman, BL; Turncliff, RZ | 1 |
| Dixon, R; Frye, RF; Matzke, GR; Rabinovitz, M; Schade, R | 1 |
1 review(s) available for naltrexone and Liver Diseases
| Article | Year |
|---|---|
Treatment of alcohol use disorder in patients with liver disease.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Liver Diseases; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2022 |
2 trial(s) available for naltrexone and Liver Diseases
| Article | Year |
|---|---|
Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Liver Diseases; Male; Middle Aged; Naltrexone; Olanzapine; Renal Insufficiency; Tablets; Young Adult | 2019 |
Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment.
Topics: Adult; Aged; Delayed-Action Preparations; Female; Humans; Liver Diseases; Male; Middle Aged; Naltrexone; Narcotic Antagonists | 2005 |
5 other study(ies) available for naltrexone and Liver Diseases
| Article | Year |
|---|---|
Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease.
Topics: Adult; Alcoholism; Humans; Liver Cirrhosis; Liver Diseases; Naltrexone; Retrospective Studies | 2022 |
Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet.
Topics: Aged; Antipsychotic Agents; Drug Combinations; Female; Humans; Liver Diseases; Male; Middle Aged; Models, Biological; Naltrexone; Narcotic Antagonists; Olanzapine; Severity of Illness Index; Tablets | 2021 |
Activation of the δ-opioid receptor inhibits serum deprivation-induced apoptosis of human liver cells via the activation of PKC and the mitochondrial pathway.
Topics: Apoptosis; bcl-2-Associated X Protein; Cytochromes c; Enkephalin, Leucine-2-Alanine; Gene Expression; Hepatocytes; Humans; Liver; Liver Diseases; Membrane Potential, Mitochondrial; Mitochondria; Naltrexone; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Receptors, Opioid, delta; Serum; Signal Transduction; Stress, Physiological; Tumor Cells, Cultured | 2011 |
Nalmefene--a long-acting injectable opioid antagonist.
Topics: Clinical Trials as Topic; Costs and Cost Analysis; Dose-Response Relationship, Drug; Drug Overdose; Humans; Injections, Intravenous; Kidney Failure, Chronic; Liver Diseases; Naltrexone; Narcotic Antagonists; Postoperative Care; Respiratory Insufficiency | 1995 |
Effects of liver disease on the disposition of the opioid antagonist nalmefene.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Case-Control Studies; Female; Galactose; Glucuronates; Humans; Injections, Intravenous; Liver Diseases; Male; Matched-Pair Analysis; Middle Aged; Naltrexone; Narcotic Antagonists; Severity of Illness Index | 1997 |